Updated Results Of Phase 3 ALLELE Study Presented At 66Th American Society Of Hematology Annual Meeting Confirm Efficacy, Safety And Durability Of Novel Allogeneic Cell Therapy Tabelecleucel In Relapsed Or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Updated Results Of Phase 3 ALLELE Study Presented At 66Th American Society Of Hematology Annual Meeting Confirm Efficacy, Safety And Durability Of Novel Allogeneic Cell Therapy Tabelecleucel In Relapsed Or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a50.7%Objective ResponseRate (ORR), 23.0-month MedianDurationofResponse (DOR), and ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967049/Updated-Results-Of-Phase-3-ALLELE-Study-Presented-At-66Th-American-Society-Of-Hematology-Annual-Meeting-Confirm-Efficacy-Safety-And-Durability-Of-Novel-Allogeneic-Cell-Therapy-Tabelecleucel-In-Relapsed-Or-Refractory-Epstein-Barr-Virus-Positive-Post-Transplant-Lymphoproliferative-Disease-EBV-PTLD
2024-12-07
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a50.7%Objective ResponseRate (ORR), 23.0-month MedianDurationofResponse (DOR), and ...
Updated Results Of Phase 3 ALLELE Study Presented At 66Th American Society Of Hematology Annual Meeting Confirm Efficacy, Safety And Durability Of Novel Allogeneic Cell Therapy Tabelecleucel In Relapsed Or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)